- Eli Lilly (LLY) reportedly in advanced talks to buy AtaiBeckley for $9–$11/sh, a sizable premium; AtaiBeckley jumped in after-hours while Lilly stock showed little movement.
- Deutsche Bank cut 2026 sales forecast for Eli Lilly’s obesity drug Foundayo to $1.3B from ~$3B. Lilly says prescriptions may rise as familiarity grows; next months will show market gap vs Wegovy.
- Citigroup kept Buy on Eli Lilly (LLY) and raised its price target to $1,600 from $1,500, updating the bank’s valuation for the stock.
- Eli Lilly’s neuroscience sales reached about $1.39B in 2025. Alzheimer’s drug Kisunla contributed roughly $249M as the company expands its neuroscience business through major deals.
TradingView
Key facts: LLY weighs AtaiBeckley buy; DB cuts Foundayo; Citi raises PT
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:LLY
- Language
- English (India)
Eli Lilly (LLY) reportedly in advanced talks to buy AtaiBeckley for $9–$11/sh, a sizable premium; AtaiBeckley jumped in after-hours while Lilly stock showed little movement.Deutsch